ArticleFrontiers in behavioral neuroscience2025
Customized SAM-Med3D with multi-view adapter and T2-FLAIR mismatch features for glioma IDH genotyping and grading.
Article in Frontiers in behavioral neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gliomas, the most aggressive type of brain tumor, are infamous for their low survival rates. Tumor grading and isocitrate dehydrogenase (IDH) status are key prognostic biomarkers for gliomas. However, obtaining these markers typically requires invasive methods such as biopsy. As an effective, noninvasive alternative, multimodal MRI can reveal tumor spatial information and the microenvironment. Low-grade and IDH-mutant gliomas often exhibit T2-FLAIR mismatch signals. Medical image foundational models can explore complex representations in medical images, and fine-tuning them may further enhance glioma diagnosis. Methods: We propose a multi-task network, MTSAM, for simultaneous glioma IDH genotyping and grading. MTSAM first uses dilated convolutions to simulate large-field convolutions and then reviews the T2 and FLAIR images. Then, we employ convolutions to perform a detailed exploration of the T2 and FLAIR images, and we subtract the weighted T2 and FLAIR images to obtain T2-FLAIR mismatch features. T2-FLAIR mismatch features are concatenated with multimodal MRIs and input into the customized SAM-Med3D. The customized SAM-Med3D is fine-tuned by leveraging complementary information across multi-view modalities, including MRIs, handcrafted radiomics (HCR), and clinical features. Then it extracts deep features for accurate IDH genotyping and grading. Results: MTSAM achieves AUCs of 92.38 and 94.31% for glioma IDH typing and grading on the UCSF-PDGM dataset, respectively, and AUCs of 91.56 and 93.37% on the BraTS2020 dataset, outperforming other methods. Additionally, we use Grad-CAM to visualize the attention maps of MTSAM, demonstrating its potential for non-invasive glioma diagnosis. Conclusion: The proposed method demonstrates that we can effectively fuse multi-view, non-invasive information and fully explore the knowledge learned by medical image foundational models from large-scale medical datasets to facilitate glioma diagnosis, thereby advancing glioma research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.